News

The novel formulation of edaravone, which was approved in May 2017, will be assessed in a cohort of 150 patients with amyotrophic lateral sclerosis for 48 weeks of treatment.

The benefits of a multidisciplinary hub for disease management can mitigate the costs.

With Theranica’s Nerivio Migra acute migraine device named a top invention of the year, three experts in migraine shared their insight into its clinical application in the early days of its availability, with varying experiences.

The Chairman of the Neurological Institute at Cleveland Clinic shared his experience with telemedicine and how he foresees it supplementing the current care offered in movement disorders.

Although there are no cures for MS at present, the treatment landscape has changed significantly, with over a dozen approved disease-modifying therapies (DMTs) representing multiple classes of agents with different mechanisms of action.

Top line results from the phase 3 trial of sovateltide in patients with acute cerebral ischemic stroke are expected by mid-2020.

The label update includes adjustments to the withdrawal risk section and a new subsection for its use in specific populations.

Midazolam nasal spray CIV, marketed under the brand name Nayzilam, is expected to become available in retail pharmacies early next month after its approval for the treatment of intermittent, stereotypic episodes of frequent seizure activity in epilepsy.

The private-public partnership aims to share patient data in hopes of uncovering new biomarkers related to Parkinson disease.

The use of cerebrospinal neurofilament light chain and TAR DNA‐binding protein 43 in tandem may offer stronger biomarkers for amyotrophic lateral sclerosis diagnosis, with NfL also offering a measure of disease progression.

Fenfluramine is set for priority review by the FDA with a PDUFA date of March 25, 2020.

The senior research scientist at Kessler Foundation offered her personal experience in treating spatial neglect in patients with stroke and potential future treatments on the way.

After receiving a complete response letter from the FDA in January, Sunovion Pharmaceuticals has resubmitted its NDA for apomorphine sublingual film, also known as APL-130277.

The FDA set a PDUFA date for risdiplam of May 24, 2020. The full 12-month data from the SUNFISH trial are expected to be presented at an upcoming medical meeting.

The chief medical officer at SK Life Science discussed what the sodium channel antagonist will offer those treating partial-onset seizures.

Neurology News Network for the week ending November 23, 2019.

The approval is supported by several studies which demonstrated the drug’s bioequivalence to Rilutek, the liquid riluzole formulation marketed by Sanofi.

Results from the phase 3 EVOLVE-MS-2 study demonstrate superior tolerability for now-approved diroximel fumarate compared to dimethyl fumarate.

The director of the Epilepsy Center and vice chair of the Neurological Institute for Strategy and Development at Cleveland Clinic detailed the transition patients and doctors make from the office to telemedicine.

The mesenchymal stem cell-neurotrophic factor cells met the primary safety end point and displayed early but promising signs of efficacy, prompting excitement among investigators for moving forward with phase 3 study.

SK Life Science’s sodium channel antagonist cenobamate was approved based on data from pivotal trials in nearly 2000 patients in which it reduced the median number of seizures per 28 days.

The phase 1/2 trial seeks to will assess the safety and efficacy of mesenchymal stem cells for the treatment of Alzheimer disease.

The Chairman of the Neurological Institute at Cleveland Clinic spoke to the history of neuromodulation and how it has evolved in clinical practice today.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, sat down to discuss the challenges faced in diagnosing Lewy body dementia.

Findings of a phase 2 assessment has suggested that otaplimastat can be safely administered in patients with stroke who are being treated with recombinant tissue plasminogen activator and is realistic to be further studied.

No progressive or delayed complications of treatment were recorded after 3 years in patients with essential tremor who underwent focused ultrasound.

The investigational new drug application for OWP Pharmaceuticals’ first-ever liquid formulation of topiramate, intended to offer a new delivery alternative for the therapy in epilepsy and migraine treatment, has been approved.

The spine surgeon in the Center for Spine Health at Cleveland Clinic discussed the importance of patient-reported outcomes for patients who are undergoing spine surgery.